With a market cap of $356.2 billion, North Chicago, Illinois-based AbbVie Inc. (ABBV) operates in the pharmaceutical sector.

AbbVie and Aliada Therapeutics have announced a definitive agreement under which AbbVie will acquire Aliada, a biotechnology ...

AbbVie Inc. raised its full-year profit forecast as demand for its top-selling anti-inflammatory drugs, Rinvoq and Skyrizi, ...

With a new way to break the blood-brain barrier, an Aliada Therapeutics deal could give the North Chicago drugmaker's ...

In a report released today, Srikripa Devarakonda from Truist Financial maintained a Buy rating on AbbVie (ABBV – Research Report). The ...

EvolveImmune Therapeutics Inc., a Branford-based bioscience company developing therapeutics to overcome cancer cell ...

The foundation donation will go toward construction of UChicago Medicine's $815 million freestanding cancer care center in ...

AbbVie (NYSE: ABBV) and EvolveImmune Therapeutics, an immuno-oncology company developing next-generation biotherapeutics to overcome the therapeutic challenges of cancer cell resistance to current ...

Evolveimmune Therapeutics Inc. has secured its fourth big pharma investor and its first pharma development partnership in a ...

NORTH CHICAGO, Ill. — NORTH CHICAGO, Ill. — AbbVie Inc. (ABBV) on Wednesday reported third-quarter profit of $1.56 billion. On a per-share basis, the North Chicago, Illinois-based company said it had ...

“We’re really excited and proud to have the opportunity to support University of Chicago Medicine and the South Side community in this way,” said Claudia Carravetta, vice president corporate ...